NCT05380063View on ClinicalTrials.gov

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

PHASE4CompletedINTERVENTIONAL
Enrollment

2,300

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

July 8, 2025

Study Completion Date

July 10, 2025

Conditions
Coronary Artery DiseaseCoronary Artery Bypass GraftingDual Antiplatelet TherapyBleedingMyocardial InfarctionMyocardial IschemiaAngina Pectoris
Interventions
DRUG

De-escalated Dual Antiplatelet Therapy

ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.

DRUG

Dual Antiplatelet Therapy

Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.

Trial Locations (1)

Unknown

Fuwai Hospital, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV